Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025. The finerenone group received conventional th...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2026-12-01
Edice:	Renal Failure
Témata:	IgA nephropathy finerenone non-steroidal mineralocorticoid receptor antagonist (MRA) proteinuria eGFR decline real-world evidence
On-line přístup:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2644719
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!